Date/Time
Date(s) - 24 Feb 2026
8:00 AM - 9:00 AM
Join AZBioPEERS for ‘Tales from the Road’.
A conversation with Terrence Stull, MD, President and Chief Scientific Officer of BacVax, as he shares his journey from academic medicine and clinical research leadership to biotech entrepreneurship. Drawing on decades of experience in pediatric infectious diseases, NIH-funded research, and healthcare system leadership, Dr. Stull will discuss the path that led to the development of BacVax’s bacterial vaccine platform and the company’s evolution within the vaccine innovation space. This session will explore lessons learned along the way, including translating research into commercial opportunity, building a company around scientific discovery, and navigating the challenges and opportunities of biotech entrepreneurship.
Tuesday, February 24, 2026
8:00 am – 9:00 am AZ
on Zoom
Register Here
Terrence Stull, MD, President & Chief Science Officer, BacVax
Dr. Stull, is President and Chief Scientific Officer of BacVax, where he leads the administrative and scientific direction of the company’s development of Bacterial Vaccine Polypeptides. He earned his MD from the University of Alabama at Birmingham, completed residency training at Stanford University, and pursued fellowship training in Pediatric Infectious Diseases at the University of Washington.
Dr. Stull practiced medicine for more than 30 years and led an NIH-funded research program focused on Haemophilus influenzae pathogenesis for over 25 years. He previously served as Chair of the Department of Pediatrics at the University of Oklahoma Health Sciences Center for 22 years, during which time the department’s annual operating budget grew from $15 million to $120 million. Most recently, he served as Senior Vice President of Research at Phoenix Children’s Hospital, overseeing more than 500 clinical research studies.
Dr. Stull is also a professor at the University of Arizona College of Medicine–Phoenix, where he led the research that resulted in the Bacterial Vaccine Polypeptide platform.